Okogen, Inc., a clinical-stage biotechnology company, announced that the first patient has been dosed in the EMERALD Trial, a multicenter Phase 1/2 study evaluating Treyegen™ (OKG-0303) for acute infectious conjunctivitis. The dosing occurred at Ambade Eye Hospital in Nagpur, India, according to the company's announcement.
The EMERALD Trial represents a significant clinical milestone for Okogen and its lead candidate, Treyegen™. The investigational therapy is being developed as a single ophthalmic treatment that combines antiviral, antibacterial, and symptom-relieving mechanisms. This multifaceted approach is designed to address acute infectious conjunctivitis, a condition where the underlying cause—viral or bacterial—is often unknown at the time of diagnosis. By targeting multiple pathways, Treyegen™ aims to provide a comprehensive treatment option that could simplify management and improve patient outcomes.
The trial will assess the safety, tolerability, clinical outcomes, and viral and bacterial activity of Treyegen™. These data will be critical in determining the therapy's potential to become a new standard of care for acute infectious conjunctivitis, which affects millions of people worldwide and is a common reason for eye care visits. Current treatments often rely on broad-spectrum antibiotics, which may be ineffective against viral infections and contribute to antibiotic resistance. A host-directed antiviral approach could offer a more precise and effective alternative.
Okogen's broader strategy centers on its ranpirnase platform, a broad-spectrum, host-directed antiviral technology. The company is advancing ranpirnase-based therapies across four therapeutic pillars: ophthalmology, medical countermeasures, systemic antivirals, and dermatology. Ophthalmology serves as the lead clinical proving ground for the platform, with the goal of applying clinical insights, formulation expertise, and manufacturing capabilities across a broader portfolio of antiviral therapies. The EMERALD Trial is therefore not only a test of Treyegen™ but also a validation of the ranpirnase platform's potential across multiple disease areas.
For more details on the announcement, click here. Additional information about Okogen and its pipeline is available at www.okogen.com.
The successful initiation of the EMERALD Trial underscores Okogen's progress in developing innovative antiviral therapies. If the trial demonstrates positive results, Treyegen™ could fill a significant unmet need in ophthalmology, providing a much-needed option for acute infectious conjunctivitis. Moreover, the insights gained from this study may accelerate the development of other ranpirnase-based therapies, reinforcing Okogen's position in the antiviral landscape.


